Tideglusib is primarily researched for its potential therapeutic applications in neurodegenerative diseases. It has shown promise in the treatment of Alzheimer's disease by inhibiting glycogen synthase kinase-3 (GSK-3), an enzyme implicated in the formation of tau tangles, a hallmark of the condition. Additionally, Tideglusib is being explored for its neuroprotective effects in other disorders such as progressive supranuclear palsy and myotonic dystrophy. Its ability to modulate GSK-3 activity also makes it a candidate for studies in mood disorders and certain types of cancer. Clinical trials are ongoing to further evaluate its efficacy and safety in these areas.